Investors

We maintain a transparent, comprehensive dialogue with the financial community about our strategy, outlook, financial data, economic environment, and social impact.

/assets/dotcom/content-app/events/banner-investors-events_20230703194346.jpg

First Quarter 2025

First quarter 2025 results were reviewed by management during a live audio webcast with the financial community. The presentation was followed by a Q&A session.

Thursday April 24, 2025
13:00 - 14:30 CEST (7:00am – 8:30am EDT)

Press Releases


April 29, 2025
Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race

April 25, 2025
Media Update: Sanofi’s Foundation S and Sobi extend their partnership with the World Federation of Hemophilia Humanitarian Aid Program

April 24, 2025
Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed

Upcoming Events

30Apr

2025

Annual General Meeting 2025

The Sanofi General Meeting will be held on April 30, 2025 at the Palais des Congrès in Paris, Porte Maillot. It will be live video webcasted.

14:30 - 16:30

Annual general meetings

Discover more

8May

2025

Berenberg R&D Leaders: Back to the Future

08:00 ET (Boston)

Conferences


13May

2025

ODDO BHF Sustainability Forum

Paris

Conferences


Karine Roblot, wearing a light green protective suit, operating steel equipment with lots of valves, gauges and tubing
Karine Roblot, Vaccine Formulation Technician, Val de Reuil, France

2024 20-F

Presenting our 2024 FORM 20-F.

Dividend Increase

Expected for the 30th consecutive year​, submitted to the annual general meeting vote on April 30th, 2025.

Dr. Lingaraju checks the health of Manikantan as his sister Geetha watches closely inside the Billigiri Ranganathaswamy Temple Tiger Reserve in Chamrajanagara district, Karnataka state, India

Environment, Social, Governance

As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges.

Contact Our Investor Relations Team

For general inquiries
Please contact the switchboard, +33 (0)1 53 77 40 00